Harmonizing the Pre-Analytical Factors to Promote Compatibility of Using ctDNA as a Surrogate Endpoint in Advanced Tumors
Time: 12:00 pm
day: Day Two Track A AM
Details:
- Correlating ctDNA changes after treatment with long term outcome
- Standardizing ctDNA molecular response rate which may be used in randomized studies
- Refining the potential of ctDNA as a surrogate endpoint by advising future directions
